Comparative Pharmacology
Head-to-head clinical analysis: ATACAND HCT versus MICARDIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND HCT versus MICARDIS.
ATACAND HCT vs MICARDIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ATACAND HCT is a combination of candesartan, an angiotensin II receptor blocker (ARB), and hydrochlorothiazide, a thiazide diuretic. Candesartan blocks the vasoconstrictor and aldosterone-secreting effects of angiotensin II by selectively antagonizing the AT1 receptor, leading to vasodilation and reduced blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the nephron, increasing sodium, chloride, and water excretion, thereby reducing plasma volume and blood pressure.
Telmisartan is an angiotensin II receptor antagonist (ARB) that selectively and competitively blocks the binding of angiotensin II to the AT1 receptor, resulting in vasodilation, reduced aldosterone secretion, and decreased blood pressure.
One tablet orally once daily. Initial dose: 16 mg candesartan/12.5 mg hydrochlorothiazide. Titrate to maximum 32 mg candesartan/25 mg hydrochlorothiazide once daily.
40-80 mg orally once daily.
None Documented
None Documented
Candesartan: ~9 hours (terminal). Hydrochlorothiazide: 6-15 hours (terminal, mean ~10 hours).
Terminal elimination half-life is approximately 24 hours (range 20-30 hours), supporting once-daily dosing. Steady-state achieved in 5-7 days.
Candesartan: ~33% renal, ~67% biliary/fecal. Hydrochlorothiazide: >95% renal.
Primarily biliary/fecal (approximately 60% as unchanged drug); renal elimination accounts for about 40% (mostly unchanged drug and inactive metabolites). Total recovery in feces: 60-70%; urine: 30-40%.
Category C
Category C
Angiotensin II Receptor Blocker / Thiazide Diuretic
Angiotensin II Receptor Blocker